News

InSphero Granted Hanging Drop Patents in China and Japan Schlieren, Switzerland, February 27, 2014 – InSphero adds GravityPLUS™ patents in major Asian markets to existing

JBS Publication Demonstrates Utility of InSphero 3D Co-culture Microtissues as Phenotypic RNAi Screening Tool Schlieren, Switzerland, February 27, 2014 – Report in the Journal of

InSphero Study Reveals Enhanced Stress-Responsive & Metabolic Gene Expression in 3D Liver Microtissues Schlieren, Switzerland, January 30, 2014 – Publication in the Journal of Tissue

InSphero hires new Director of Global Marketing Schlieren, Switzerland, January 28, 2014 – InSphero starts 2014 with a new Director of Global Marketing: Randy Strube,

InSphero's new EU subsidiary opens for business Schlieren, Switzerland, November 25, 2013 - After successfully launching its US office in April this year, InSphero has

InSphero in TOP 10 Start-Ups for the third time in as many years Schlieren, Switzerland, October 10, 2013 - For the third year running, InSphero

A 3D InSight™ into drug discovery with Tecan's Infinite® M200 PRO Schlieren, Männedorf, Switzerland, July 16, 2013 – A novel solution for analyzing 3D cell

InSphero secures CHF 2 Million in Financing Zurich, Switzerland, June 13, 2013 – InSphero AG, experts in three-dimensional microtissue technology, has secured CHF 2 Million

InSphero ranked #2 Startup of the Year in Switzerland Zurich, Switzerland, November 5, 2012 – InSphero AG, experts in three-dimensional microtissue technology, is proud to

Cyprotex will offer a new long-term toxicity testing service using InSphero's 3D InSight™ Liver Microtissues Zurich, Switzerland, 13. September 2012 – InSphero AG, experts in three-dimensional microtissue

InSphero will coordinate the European Union project to develop a next-generation test device for pharmaceutical drug screening Zurich, Switzerland, 24 July 2012 – InSphero, a

New 3D InSight™ Human Liver Microtissues make it much easier to screen pharmaceutical compounds for repeat-dose and inflammation-related toxic effects Zurich, Switzerland, 2. July 2012